Are you a Health Professional? Jump over to the doctors only platform. Click Here

Multiple Sclerosis (MS)

brain illustration

What is Multiple Sclerosis (MS)

Multiple sclerosis (MS) is a disease of the central nervous system (brain and spinal cord). Nerves in the body are covered with a fatty sheath called myelin. Myelin considerably increases the speed that nerve signals (impulses) travel down the axons. A thin myelinated axon transmits impulses at anything from 5 to 30 meters per second, whereas an unmyelinated one transmits them at 0.5 to 2 meters per second. It does this by both insulating and containing the nerves.

In MS, there are multiple areas of damage to the myelin sheath (demyelination) within the brain and spinal cord. This causes conduction problems within the central nervous system. The peripheral nervous system is not usually involved but may be subtly. MS can manifest in different ways, including:

  • Relapsing remitting;
  • Primary progressive;
  • Secondary progressive (when relapsing and remitting disease becomes progressive); and
  • Progressive relapsing (a combination of relapsing remitting and progressive from the outset).

Statistics on Multiple Sclerosis (MS)

MS is one of the most common causes of chronic neurological disability in adults, and affects approximately one million people worldwide. The disease usually starts in early adult life (20–45 years) and causes progressive disability over several decades. MS is more common in women, who outnumber males by a ratio of 2:1.

The prevalence of MS is directly proportional to distance from the equator. At 50–65 degrees latitude (north or south), the prevalence is 60–100 per 100,000 people. At the equator, MS is a rarity. The incidence, however, is very variable.

Approximately one in 3,000 Australians are affected by the disorder.

Risk Factors for Multiple Sclerosis (MS)

Multiple sclerosisThe exact cause of MS is not entirely understood, but it is thought to be due to a number of genetic, environmental and immune factors. It is hypothesised that individuals with a genetic predisposition who are infected with certain viruses induce an immune response that attacks their own nerve cells.

Risk factors for MS therefore include:

  • Latitude: Latitude is more strongly related to MS than any other risk factor. Risk of MS increases when an individual lives further away from the equator. If you migrate to a high-risk area before the age of 15, you will have the same high risk as those who were born in the area. Therefore, your risk of MS reflects that of the area in which you spent your first 15 years.
  • Sex: MS affects females more than males, but the reason for this difference is unknown.
  • Family history: If you have a first degree relative with MS, you are 15 times more likely than the general population to suffer from MS (this is still a very low risk). Twins from the same egg (monozygotic) are more likely to have MS than those from separate eggs (dizygotic) if one twin is affected.
  • Race: MS presents more often in populations of northern European ancestry.
  • Vitamin D Status: Low levels of vitamin D exposure result in an increased risk of MS.
  • Smoking: smokers have an increased risk of developing MS
  • Epstein-Barr Virus: Exposure to EBV increases the risk of MS
  • Diet: It is thought that diets high in animal fats may increase the risk of MS, due to observations that MS is uncommon in coastal communities where large amounts of fish are consumed.

Progression of Multiple Sclerosis (MS)

Most patients have a relapsing/remitting disease, where they have discrete attacks of symptoms (such as loss of vision and limb sensations/weakness) that last weeks to months and then completely resolve. These attacks may not have a clear precipitant, and on average tend to occur once every two years. These attacks or relapses should be distinguished from minor exacerbations of previous symptoms which can occur with increases in body temperature. Later in the course of the disease, patients may not fully recover from attacks and experience progressive disability. This is the secondary progressive form of disease, which occurs in 50% of patients after 15 years. The majority of MS cases will eventually evolve into the secondary progressive form.

Some patients may have only one or two attacks and may fully recover from these attacks. In other patients, the disease will progress and produce severe disability, or even death.

Other patients have primary progressive disease, which shows a rapid decline in function without any acute attacks. This occurs in approximately 20% of patients and affects males and females equally. However, males with this disorder have the worst prognosis, as spinal cord involvement leads to early disability.

The final type of MS is relapsing progressive, affecting 5% of patients. This is an overlap of the former types, characterised by a progressive course from the onset but with additional superimposed acute attacks.

Symptoms of Multiple Sclerosis (MS)

Multiple sclerosisAs MS can affect virtually anywhere in the CNS, a wide variety of neurological manifestations are possible. However, some of the major patterns of symptoms aside from weakness and loss of sensation/pain include:

  • Fatigue (the most common symptom);
  • Blurred vision and mild pain of the eye due to damage to the optic nerve;
  • Diplopia (double vision), vertigo, facial numbness and weakness or dysphagia due to brainstem demyelination;
  • Ataxia (imbalance) and tremor;
  • Spasticity (sometimes with spasms) with difficulty walking, urinary dysfunction, and sexual dysfunction;
  • Mood alteration.

Your doctor will take a detailed history of your symptoms and try to determine whether you fit a relapsing/remitting or progressive form of the disorder. The diagnosis of MS relies on the demonstration of symptoms that are separated in time and anatomical location, and are unexplained by another condition.

Clinical Examination of Multiple Sclerosis (MS)

Your doctor will perform a complete neurological examination, including testing your gait (walking), sensation and vision. They will also use a device called an ophthalmoscope to look at the retina at the back of the eye. This can identify abnormalities of the optic disc caused by optic neuritis. Double vision, nystagmus (oscillating movements of the eyes) and loss of vision are other signs often found on examination.

How is Multiple Sclerosis (MS) Diagnosed?

MS can usually be diagnosed by careful history and examination as there are very few neurological conditions of young people that follow a similar relapsing and remitting course. However, some patients may not have the classical signs, or may be affected at a very young or older age. In these patients, further investigation may be needed to exclude other medical conditions, such as vasculitis, sarcoidosis, encephalitis, tuberculosis, brain tumours, Alzheimer’s disease and vitamin B12 deficiency.

The most common investigations for MS include:

  • MRI: This is the first-line investigation. MRI may show plaques of demyelination in the spinal cord and brain.
  • Electrophysiological testing (evoked potentials): This measures the nerve potentials in visual, auditory and somatosensory pathways, and can detect whether nerves have been damaged and conduction delayed.
  • Lumbar puncture: Analysis of spinal fluid by lumbar puncture may show raised numbers of cells during acute attacks. Between attacks, there may be local production of antibodies (known as oligoclonal bands).
  • Electroencephalogram: EEG is mainly used to exclude other conditions such as encephalitis, but usually the clinical differentiation of this condition is not difficult.

Prognosis of Multiple Sclerosis (MS)

There is no way to predict the course of MS in a patient. In some, the disease will not affect them much and they will be able to continue their normal lives, others may have considerable disability. Overall, patients with MS are said to have a life expectancy 7 years less than the general population. Most deaths occur from complications of disability (such as recurrent infections in bedridden patients) rather than from acute attacks.

The following factors may be associated with a worse prognosis:

  • Bowel and/or bladder symptoms at onset
  • Short interval between first and second attacks
  • Incomplete remission after first relapses
  • Early disability
  • High relapse rate in early years
  • High lesion load detected by MRI during early years of illness
  • Male sex, though this has been contradicted by more recent research
  • Older age at onset, though this has been contradicted by more recent research
Brain MRI

How is Multiple Sclerosis (MS) Treated?

Multiple sclerosisThere are a number of different treatments available for MS to reduce the severity and frequency of exacerbations, and possibly to alter the progression of disability later on. However, to date, no drug has been found that can halt or reverse the progression of disease. This would require a drug that can perform the difficult task of remyelination of damaged nerves.

Your doctor will discuss the best treatment for you based on the severity and type of your condition. This may include some of the following treatments:

  • Corticosteroids: Methylprednisolone is the usual treatment given in acute attacks to reduce their severity.
  • Beta-interferon: (Betaferon, Avonex, Rebif): This drug is given by a subcutaneous injection and can reduce the rate of relapses by a third. This is often the first-line treatment for relapsing/remitting disease.
  • Glatiramer acetate (Copaxone): This drug is another immunomodifier that also reduces the frequency and severity of attacks.
  • Oral immunosuppressants: Immunosuppressants have been recently developed and show promise in reducing the number of attacks.
  • Other immunosuppressant medications such as azothioprine and cyclophosphamide are used in some patients and can reduce relapses. However they do not decrease the number of lesions seen on MRI as well as the former drugs.
  • Muscle relaxants (baclofen, dantrolene, benzodiazepines): Can reduce the discomfort and pain of spasticity.
  • Oxybutinin, a bladder muscle antispasmodic, and intermittent urinary catheterisation (inserting a thin tube via the urethra to empty the bladder): May help urinary incontinence.
  • Physiotherapy and occupational therapy: Have an extremely important role.

 

Article kindly reviewed by:

Associate Professor Karl Ng MB BS (Hons I) FRCP FRACP PhD CCT Clinical Neurophysiology (UK) Consultant Neurologist – Sydney North Neurology and Neurophysiology (download referral form and map); Conjoint Associate Professor – Sydney Medical School, University of Sydney; and Editorial Advisory Board Member of the Virtual Neuro Centre.

More information

Multiple sclerosisFor more information on multiple sclerosis and symptoms associated with this disease, see Multiple Sclerosis (MS).
Movement disordersFor more information on neurological disorders that affect movement, and their treatments, see Neurological Rehabilitation and Movement Disorders.

Multiple Sclerosis (MS) References

  1. Trapp BD, Nave KA. Multiple sclerosis: An immune or neurodegenerative disorder? Annu Rev Neurosci. 2008;31:247-69. [Abstract]
  2. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502-17. [Abstract]
  3. Kumar P, Clark M (eds). Clinical Medicine (5th edition). Philadelphia: WB Saunders Company; 2002.
  4. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: A geographically based study: 1. Clinical course and disability. Brain. 1989;112(1):133-46. [Abstract]
  5. Ng K, Howells J, Pollard JD, et al. Upregulation of slow K+ channels in peripheral motor axons: A transcriptional channelopathy in multiple sclerosis. Brain. 2008;131(11):3062-71. [Abstract | Full text]
  6. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology. 1996;46(4):907-11. [Abstract]
  7. Pugliatti M, Rosati G, Carton H, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol. 2006;13(7):700-22. [Abstract | Full text]
  8. Longmore M, Wilkinson I, Rajagopalan S. Oxford Handbook of Clinical Medicine (6th edition). London: Oxford University Press; 2004.
  9. Kasper DL, Braunwald E, Fauci AS, et al. Harrison’s Principles of Internal Medicine (16th edition). Columbus: McGraw-Hill; 2005.
  10. McLeod JG, Hammond SR, Hallpike JF. Epidemiology of multiple sclerosis in Australia. With NSW and SA results. Med J Aust. 1994;160(3):117-122. [Abstract]
  11. Cotran RS, Kumar V, Collins T, Robbins SL. Robbins Pathologic Basis of Disease (6th edition). Philadelphia: WB Saunders Company; 1999.
  12. Lauer K. Ecologic studies of multiple sclerosis. Neurology. 1997;49(2 Suppl 2):S18-26. [Abstract]
  13. Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol. 2008;7(3):268-77. [Abstract]
  14. Sadovnick AD, Ebers GC, Dyment DA, et al. Evidence for genetic basis of multiple sclerosis. Lancet. 1996;347(9017):1728-30. [Abstract]
  15. Willer CJ, Dyment DA, Risch NJ, et al. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc Natl Acad Sci U S A. 2003;100(22):12877-82. [Abstract | Full text]
  16. Ascherio A, Munger K. Epidemiology of multiple sclerosis: From risk factors to prevention. Semin Neurol. 2008;28(1):17-28. [Abstract]
  17. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol. 2007;61(6):504-13. [Abstract]
  18. Riise T, Nortvedt MW, Ascherio A. Smoking is a risk factor for multiple sclerosis. Neurology. 2003;61(8):1122-4. [Abstract]
  19. Confavreux C, Hutchinson M, Hours MM, et al. Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med. 1998;339(5):285-91. [Abstract]
  20. Sadovnick AD, Ebers GC, Wilson RW, et al. Life expectancy in patients attending multiple sclerosis clinics. Neurology. 1992;42(5):991-4. [Abstract]
  21. Redelings MD, McCoy L, Sorvillo F. Multiple sclerosis mortality and patterns of comorbidity in the United States from 1990 to 2001. Neuroepidemiology. 2006;26(2):102-7. [Abstract]
  22. Deshpande R, Kremenchutzky M, Rice GP. The natural history of multiple sclerosis. Adv Neurol. 2006;98:1-15. [Abstract]
  23. Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology. 2006;66(2):172-7. [Abstract]
  24. Langer-Gould A, Popat RA, Huang SM, et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: A systematic review. Arch Neurol. 2006;63(12):1686-91. [Abstract | Full text]
  25. Brex PA, Ciccarelli O, O’Riordan JI, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 2002;346(3):158-64. [Abstract | Full text]
  26. Weinshenker BG. Natural history of multiple sclerosis. Ann Neurol. 1994;36 Suppl:S6-11. [Abstract]
  27. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol. 1983;13(3):227-31. [Abstract]
  28. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121-7. [Abstract]
  29. Wolinsky JS. The diagnosis of primary progressive multiple sclerosis. J Neurol Sci. 2003;206(2):145-52. [Abstract]
  30. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005;58(6):840-6. [Abstract]
  31. Royal College of Physicians of London. Management of multiple sclerosis in primary and secondary care [online]. London: National Institute for Health and Clinical Excellence; 26 November 2003 [cited 27 November 2008]. Available from: [URL link]
  32. Kurtzke JF. Rating neurological impairment in multiple sclerosis: An expanded disability scale (EDSS). Neurology. 1983;33(11):1444-52. [AbstractFull text]
  33. Polman C, Uitdehaag B. Drug treatment of multiple sclerosis. BMJ. 2000;321(7259):490-4. [Abstract | Full text]
  34. Gorelick L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010; 68(3): 295-303. [Abstract]

Dates

Posted On: 11 September, 2003
Modified On: 2 March, 2014
Reviewed On: 7 February, 2012

Tags



Created by: myVMC